AMGEN'S REPATHA® CUTS RISK OF FIRST MAJOR ADVERSE CARDIOVASCULAR EVENTS BY 25% IN LANDMARK PHASE 3 VESALIUS-CV TRIAL

Evolocumab lowers risk for first major cardiovascular events

NEW ORLEANS — In patients with atherosclerosis and/or diabetes without a prior heart attack or stroke, evolocumab cut the risk for first major adverse CV events by 25% compared with placebo, according to results of the VESALIUS-CV trial.Lowering LDL cholesterol with PCSK9 inhibitors, including evolocumab (Repatha, Amgen), lowers risk for CV events in patients with a prior major

AMGEN'S REPATHA® CUTS RISK OF FIRST MAJOR ADVERSE CARDIOVASCULAR EVENTS BY 25% IN LANDMARK PHASE 3 VESALIUS-CV TRIAL

Amgen (NASDAQ: AMGN) reports Repatha cut heart attack risk 36% in Phase 3 VESALIUS-CV

Phase 3 VESALIUS-CV in 12,000+ high-risk adults without prior heart attack or stroke showed 19% 4-P MACE reduction; median LDL-C 45 vs 109 mg/dL; no new safety signals.

PCSK9 Inhibitor Shows Significant Reduction in First Major Cardiovascular Events in High-Risk Patients

Adding the PCSK9 inhibitor evolocumab to high-intensity cholesterol-lowering regimens significantly reduces the risk of first major cardiovascular events in adults with atherosclerotic cardiovascular disease or diabetes, according to findings from the international VESALIUS-CV clinical trial presented at the American Heart Association’s Scientific Sessions 2025. The study represents the first demonstration of improved cardiovascular outcomes wit…